ArticleInfection and drug resistance2025
Real-World Analysis of Potential Drug-Drug Interactions with Nirmatrelvir/Ritonavir Based on the Hospital Prescription Analysis (HPA) Database in 9 Cities of China.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.Clinical and experimental medicine · 2026Article
- Risk prediction model for severe potential drug-drug interactions in colorectal cancer patients: a real-world data study.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China. Patients and Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study. Statistical analyses included descriptive statistics (continuous variables as mean ± SD; categorical variables as counts and percentages) and multivariate binary logistic regression, which was used to identify factors associated with potential DDIs, with adjustment for confounding variables (sex, age, cities, number of co-administered drugs, comorbidities). Analyses were performed using R software (v4.2.2) with Results: Of 15,567 patients receiving NMVr, the mean age was 62.4 ±18.2 years, and 53.1% were male. 8542 patients received at least one co-administration, and 5391 patients exhibited at least one potential DDI. A total of 10,694 potential DDIs were identified, with a breakdown of 8310 grade C, 2093 grade D and 291 grade X. Systemic corticosteroids (n=3608) and drugs for obstructive airway diseases (n=2220) had the highest frequencies in grade C DDIs, and the lipid modifying agents (n=601) in grade D DDIs, and cardiac therapy drugs (n=130) in grade X DDIs. Co-administration of drugs significantly increased odds of potential DDIs with the risk escalating markedly as the number of drugs increased, and the comorbidities of hypertension (odds ratio [OR]=1.50), asthma (OR=4.28) and mental disorders (OR=7.02) significantly increased it as well. Conclusion: In this large-scale cross-sectional study in China, approximately one-third of the patients treated with NMVr were at risk of clinically significant potential DDIs, highlighting the importance of making efforts to diminish these risks, such as close monitoring and dose adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.